TEL AVIV, Israel, Aug. 9, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today announced the start of regulatory procedures to market the company's advanced cancer diagnostic solution in Russia. This follows mBeach's recent announcement on the signing of an MOU for Russia and the Commonwealth of Independent States (CIS).
Completing these regulatory procedures will pave the way for local clinical trials and a full commercial launch of SkinScan 650, SCS's non-invasive, point-of-care system to detect and identify different types of skin cancers. SCS expects to receive the initial import approval by the end of October 2010.
mBeach CEO Yossi Biderman commented, "We are excited at the prospects of entering this very large and attractive region, one of the fastest-growing healthcare markets in the world. Typically in Russia today, cancer is diagnosed at relatively advanced stages when treatment options are less effective and more costly. Our market research identifies a clear demand for advanced medical technologies such as ours for the early detection of skin cancer." Mr. Biderman further stated, "We will be working closely with our local distributor and look forward to updating our shareholders on our progress in this important market."
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.